Validating ROS1 Rearrangements As a Therapeutic Target in Non–Small-Cell Lung Cancer
Menée sur 32 patients atteints d'un adénocarcinome du poumon de stade IV présentant un réarrangement du gène ROS1, cette étude rétrospective évalue l'efficacité, du point de vue de la survie sans progression, et la toxicité du crizotinib
Initially thought to be prevalent predominantly in hematologic malignancies and sarcomas, chromosomal rearrangements leading to oncogenic gene fusions have now been described across a range of epithelial cancers, including non–small-cell lung cancer (NSCLC). In 2007, rearrangements involving the anaplastic lymphoma kinase (ALK) gene were described in NSCLC. Single-arm phase I and II studies led to accelerated approval of the first-in-class ALK inhibitor crizotinib for ALK-rearranged NSCLC. Two phase III studies confirmed the superiority of crizotinib over chemotherapy, establishing crizotinib as a standard of care for patients with NSCLC whose tumors test positive for ALK gene rearrangements. In the article that accompanies this editorial, Mazières et al report the therapeutic efficacy of targeting a second gene rearrangement in NSCLC with crizotinib, this time involving the ROS1 gene...
Journal of Clinical Oncology , éditorial en libre accès, 2015